Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trialsReport as inadecuate




Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials - Download this document for free, or read online. Document in PDF available to download.

Reference: Jayne E. Edwards and R. Andrew Moore, (2002). Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urology, 2, Article: 14.Citable link to this page:

 

Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials

Abstract: Background: Benign prostatic hyperplasia affects older men. This systematic review determined efficacy and adverse effects of finasteride.Review methods: PubMed, the Cochrane Library, reference lists of reports, and reviews were searched for randomised, double-blind trials of finasteride in benign prostatic hyperplasia. Outcomes included symptom score, urinary flow rate, prostate volume, discontinuation, and adverse effects. Relative risk and NNT or NNH were calculated for dichotomous data. Sensitivity analyses assessed influences of baseline symptom severity, initial prostate volume, a dominating trial, and previous interventions.Results: Three trials had active controls and 19 had placebo. In placebo-controlled trials, 8820 patients received finasteride 5 mg and 5909 placebo over 3-48 months. Over 48 months finasteride produced greater improvements in total symptom score, maximum urinary flow rate, and prostate volume. Significantly more sexual dysfunction, impotentce, ejaculation disorder and decreased libido occurred with finasteride at 12 months; the NNH for any sexual dysfunction at 12 months was 14. Significantly fewer men treated with finasteride experienced acute retention or had surgery at 24 or 48 months than with placebo; at 12 months the NNT was 49 (31 to 112) to avoid one acute urinary retention and 31 (21 to 61) to avoid one surgery. Sensitivity analyses showed benefit with finasteride 5 mg to be constant irrespective of the initial prostate volume.Conclusions: Information from many patients in studies of high quality showed beneficial effects of finasteride in terms of symptoms, flow rate and prostate volume. More utility would result if patient centred outcomes were reported in dichotomous form.

Publication status:PublishedPeer Review status:Peer reviewedVersion:Publisher's version Funder: Merck Sharp and Dohme Ltd, UK   Funder: Oxford Pain Relief Trust   Funder: Pain Relief   Notes:Citation: Edwards, J. E. & Moore, R. A. (2002). 'Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials', BMC Urology, 2: 14. [This article is available from: http://www.biomedcentral.com/1471-2490/2/14]. © 2002 Edwards and Moore; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Bibliographic Details

Publisher: BioMed Central Ltd.

Publisher Website: http://www.biomedcentral.com

Host: BMC Urologysee more from them

Publication Website: http://www.biomedcentral.com/bmcurol

Issue Date: 2002-December

Copyright Date: 2002

pages:Article: 14Identifiers

Doi: https://doi.org/10.1186/1471-2490-2-14

Issn: 1471-2490

Urn: uuid:1b83ff62-f79c-4a3a-a475-107bdd15aa66 Item Description

Type: Article: post-print;

Language: en

Version: Publisher's versionKeywords: benign prostatic hyperplasia finasterideSubjects: Anaesthetics Tiny URL: ora:2465

Relationships





Author: Jayne E. Edwards - institutionUniversity of Oxford facultyMedical Sciences Division - Clinical Medicine,Nuffield Department of -

Source: https://ora.ox.ac.uk/objects/uuid:1b83ff62-f79c-4a3a-a475-107bdd15aa66



DOWNLOAD PDF




Related documents